# Antibiotic prescribing patterns at children's outpatient departments of primary care institutions in Southwest China 

Wenju Wang ${ }^{1 \dagger}$, Shitao $\mathrm{Yu}^{2+}$, Xunrong Zhou ${ }^{3^{*}}$, Lei Wang ${ }^{4^{*}}$, Xun He ${ }^{5}$, Hanni Zhou ${ }^{5}$ and Yue Chang ${ }^{5^{*+} \text { © }}$


#### Abstract

Background: Inappropriate use of antibiotics in children is common in many countries. The purpose of the study was to explore patterns of antibiotic prescribing in children's outpatient clinics in primary care institutions in a province of southwest China. Methods: We obtained electronic prescription data from 75 primary care institutions in Guizhou province in 2020. The classification of incorrect spectrum of antibiotics, unnecessary use and combined use of antibiotics was based on the Guiding Principle of Clinical Use of Antibiotics (2015, China) and guidelines from the USA Centers for Disease Control and Prevention. Potential risk factors for inappropriate use of antibiotics were identified using bivariate analyses. The generalized estimation equation was used to identify independent predictors of inappropriate use of antibiotics. Results: A total of 158,267 antibiotic prescriptions were retrieved. Acute upper respiratory tract infections were the most common diseases, accounting for $74.9 \%$ of all prescriptions. The main antibiotic group used was penicillins ( $63.7 \%$ ), followed by cephalosporins ( $18.8 \%$ ). Of 137,284 visits, $18.3 \%$ of antibiotic prescriptions were appropriate and the percentage of unnecessary use, incorrect spectrum of antibiotics and combined use of antibiotics was 76.9, 2.4 and $2.4 \%$, respectively. Physicians with lower professional titles and more than 40 years of work duration were relatively more likely to prescribe inappropriate antibiotics. Conclusion: The inappropriate use of antibiotics in children is still prominent in primary care institutions of southwest China. The education and training of physicians and caregivers in these institutions should be strengthened.


Keywords: Children, Antibiotic use, Appropriateness, Primary care institution

[^0]
## Background

Antibiotic resistance (ABR) has become a major challenge in the field of global public health [1]. Inappropriate use of antibiotics not only leads to the development of ABR, but also increases various adverse reactions and the financial burden on health services [2]. In recent years, measures to control the inappropriate use of antibiotics have been implemented by health authorities, scientific research and medical institutions in many countries [3-8]. Although the prevalence of overuse and abuse of antibiotics has decreased [9-14], the number of main
pathogens of $A B R$ in pediatric patients remain high [15, 16].
The appropriate use of antibiotics in children is critical because there are limited formulations of antibiotics suitable for this population [17, 18]. Studies of antibiotic prescribing patterns among children in primary care institutions in many countries found that inappropriate antibiotic use among children ranged from 19.6 to 79.8\% [18-22]. However, children belong to a special drug using group because the organs and functions of their bodies are not fully developed. They also have unique digestive characteristics, lack of liver and kidney metabolism, and incomplete blood-brain barrier function. Antibiotic absorption, distribution, metabolism and excretion are weaker than that in adults [23]. Therefore, more attention should be paid to the inappropriate use of antibiotics in this population.
This study reviewed the antibiotic prescription data of children in outpatient clinics of primary care institutions in Guizhou, southwest China in 2020. The objective of the study was to explore patterns of antibiotic prescribing in children's outpatient clinics in primary care institutions.

## Materials and methods

## Ethics approval

The study was approved by the Review Committee of Guizhou Medical University (Approval Certificate No. 2019(149)). All participants (physicians) provided written informed consent to participate in the study.

## Study design and setting

A retrospective study was conducted in Guizhou, one of China's poorest provinces. Antibiotic prescribing patterns for children in primary care institutions were quantified from January to December 2020. The main influencing factors of inappropriate use of antibiotics were explored.
This study has been authorized by the Information Center of Guizhou Provincial Health Commission. A data collection agreement was reached with the Guizhou LianKe Weixin Co., LTD. (LWTC), which developed the electronic Hospital Information System (HIS). The data was obtained through the data port of the information center.

## Data sources

China's 3-tier hospital system, from top to bottom, includes: tertiary hospitals, secondary hospitals, and primary hospitals. Primary care institutions, which include township health centers and community health service centers, belong to primary hospitals [24]. In 2020, there were 252 public primary care institutions using the HIS
system in Guizhou Province. Seventy-five primary care institutions were randomly selected for the study. The two selection criteria were: (1) the institution contained more than three outpatient general practitioners, and (2) the physicians must have been on duty year-round during 2020. Of the one hundred and seventy-two primary care institutions that met the above criteria, 75 primary care institutions were randomly selected by LWTC staff through a random number table. We derived outpatient antibiotic prescription-related information and demographic information of patients from the HIS. The sex, age, education, title and working experience of physicians were provided by the Personnel Management Department of the primary care institutions.
People under 18 years of age who received antibiotics were included in our study, according to the definition of children's age in the United Nations Convention on the Rights of the Child [25] and Law of the People's Republic of China on the Protection of Minors [26]. The classification of diseases was based on the 10th Edition of the International Classification of Diseases (ICD-10) [27]. According to the 2018 National Catalogue for Clinical Application of Antibacterial Drugs (summarized in Additional file S1), antibiotics were classified into penicillins, cephalosporins, macrolides, quinolones, lincoamides, nitroimidazoles and aminoglycosides. We focused on systemic antibiotics; topical antibiotics such as eye drops and ointments were excluded.

## Appropriate classification of antibiotic use

Our evaluation of the appropriateness of antibiotic prescription was mainly based on the following three aspects: 1) National Health Commission of China for Guiding Principle of Clinical Use of Antibiotics introduced in 2015 (Additional file S2), 2) the United States Centers for Disease Control and Prevention (CDC) Guidelines for use of antibiotics [28], and 3) based on our previous research [29], we also added the opinions of experts familiar with the situation of domestic primary care institutions. Thus, antibiotic prescriptions in primary care institutions were divided into appropriate and inappropriate use. Appropriate use of antibiotics was further divided into two categories: 1) preferred medication: optimal drug, and 2) antibiotics can be used or substituted: available, not optimal. Inappropriate antibiotic prescribing was further divided into three categories: 1) Unnecessary use: prescribing antibiotics to prevent viral infections, 2) incorrect spectrum of antibiotics: through all kinds of antibiotic drug pharmacological action, antibacterial spectrum, adverse drug reaction and "the empirical treatment can choose antibacterial drugs according to the possible pathogenic bacteria" [17, 28] to judge, e.g., the main pathogens of acute tonsillitis and
acute pharyngitis were group A hemolytic streptococcus, and a few were Group $C$ or $G$ hemolytic streptococcus. Therefore, penicillins are preferred medication when antibiotics are treated empirically, and cephalosporins can be considered next. If the patient is allergic to penicillins, quinolones sensitive to hemolytic streptococci can be considered. Lincoamides and macrolides (bacteria such as Streptococcus pneumoniae at present are highly resistant to these two antibiotics groups, and are generally not used) also can be used or substituted. Nitroazoles mainly target anaerobic bacteria, and aminoglycosides have poor antibiotic effect on Streptococcus pneuтопiae group A hemolytic streptococcus. The use of nitroazoles and aminoglycosides in treatment was regarded as incorrect spectrum of antibiotics., and 3) combined use of antibiotics: more than one systemic antibiotic by injection or oral administration at a time by an outpatient physician without any indication, e.g., amoxicillin capsule and ceftazidime injection combined.

## Data analysis

All prescriptions were linked to physicians and patients through coding identification, forming a database of medical service information. A physician can prescribe one or more antibiotics to a patient in a day, but multiple visits per patient per day count as only one visit. Antibiotic prescribing patterns were determined by performing
bivariate cross-tabulations between ICD-10 disease classification and antibiotic groups. Potential risk factors for inappropriate use of antibiotics were also identified using a bivariate cross-tabulation. In order to explain the correlation between antibiotic prescriptions prescribed by the same physician and to avoid possible confounding effects of other variables, the generalized estimation equation (GEE) approach was used to identify independent predictors for inappropriate use of antibiotics. All $P$-values were two-sided. R version 4.1.2 was used for all data management and analysis.

## Results

During the study period, 158,267 antibiotics prescribed to 143,809 patients aged 18 years and under were obtained from the HIS. After excluding 823 antibiotic prescriptions labeled in other categories and 2310 topical antibiotic prescriptions, there were 155,134 prescriptions remaining among 143,257 patients. For the purposes of this analysis, only patients who were diagnosed with any of the top 10 common systemic diseases were included in the study, resulting in a total of 150,133 antibiotic prescriptions (96.8\%).
Figure 1 shows the number of antibiotic prescriptions per quarter in 2020. Throughout the year, penicillins were prescribed more often than other antibiotics. The second most commonly prescribed antibiotic class was


Fig. 1 Number of antibiotic prescriptions in each quarter in 2020 stratified by antibiotics classes
cephalosporins. More penicillins and cephalosporins were prescribed in the first or fourth quarter, while quinolones and nitroimidazoles showed little change in the prescription patterns across the four quarters.
Table 1 shows the distribution of clinical diagnoses, antibiotic group and antibiotic prescriptions. In columns 4-10, "P" represents "Preferred medication", "A" represents "Antibiotic can be used or substituted", "I" represents "Incorrect spectrum of antibiotics", and "U" represents "Unnecessary use". Diseases of the respiratory system accounted for $86.8 \%$ of all antibiotic prescriptions, followed by diseases of the digestive system (6.0\%) and diseases of the skin and subcutaneous tissue (2.1\%). Penicillins were used the most, accounting for $63.7 \%$ of the total prescriptions, followed by cephalosporins (18.8\%) and lincosamides (5.8\%).
The highest rate of inappropriate use was seen for symptoms, signs and abnormal clinical and laboratory finding not elsewhere classified (100\%), diseases of the circulatory system (96.9\%), and diseases of the skin and subcutaneous tissue (88.6\%). Incorrect spectrum of antibiotic was common for children with diseases of the eye and adnexa ( $37.1 \%$ ), certain infectious and parasitic diseases (13.2\%), and diseases of the ear and mastoid process ( $6.1 \%$ ). The unnecessary use of antibiotics for diseases of the ear and mastoid process and diseases of the eye and adnexa was $12.6 \%$ and $8.5 \%$, respectively. Unnecessary use of antibiotics for the other eight systemic diseases exceeded $50 \%$. Diseases of the ear and mastoid process ( $81.3 \%$ ), diseases of the eye and adnexa (54.5\%) and injury, poisoning and certain other consequences of external causes ( $47.2 \%$ ) were the top three ranked diseases in terms of appropriateness of antibiotics use.
Table 2 compares the distribution of patterns of antibiotics use by physicians' and patients-related factors. In column 5, "Combined use of antibiotics" refers to when a physician prescribes two or more groups of antibiotics for the same patient in the same visit. The percentage of different antibiotic prescription types decreased compared to Table 1 as two or more antibiotics prescribed to the same patient on the same day were considered a single visit. As shown in Table 2, the proportions of prescriptions that were "preferred medication", "antibiotic can be used or substituted", "combined use of antibiotics", "incorrect spectrum of antibiotics" and "unnecessary use" were $9.5 \%, 8.8 \%, 2.4 \%, 2.4 \%$ and $76.9 \%$, respectively. Bivariate analysis showed that all variables were statistically significant (all $P<0.001$ ). Therefore, all variables were included in the multivariate analysis.
Table 3 shows factors associated with inappropriate antibiotic use on multivariate analysis. As shown in Table 3, for physician-related factors, being male, older than 32 years, having a lower professional title, and
having a lower level of education were associated with a higher likelihood of inappropriate antibiotic use. In terms of work duration, we found that physicians with 6 to 10 years of service and those with more than 40 years of work duration were more likely to prescribe inappropriate antibiotics. For patient-related factors, females and those aged $0-1$ years had a higher likelihood of being prescribed inappropriate antibiotics. Physicians were more likely to prescribe inappropriate antibiotics in quarters 3 and 4 compared to the first quarter of 2020. Finally, children insured with the New Rural Cooperative Medical system were more likely to be prescribed inappropriate antibiotics than those who fully paid for them out-of-pocket.

## Discussion

In this retrospective study, 75 primary care institutions in Guizhou Province were selected to describe the prescription patterns of antibacterial drugs among children in 2020. Overall, the rate of antibiotic prescriptions was highest in the fourth quarter, followed by the first quarter. Among the antibiotics prescribed, penicillins and cephalosporins were the most used antibiotics groups. The most common childhood diseases were the diseases of the respiratory system ( $86.8 \%$ ), followed by diseases of the digestive system (6.0\%) and diseases of the skin and subcutaneous tissue (2.1\%). Overall, $80.5 \%$ of antibiotic prescriptions were inappropriate. Physicians with lower professional titles and more than 40 years of work duration were relatively more likely to prescribe inappropriate antibiotics.
In this study, acute upper respiratory infections of multiple and unspecified sites (J06, 58.7\%) and acute tonsillitis (J03, 13.7\%) were the most common upper respiratory diseases for which antibiotics were administered in children, accounting for $72.4 \%$. A study from China reported an antibiotic prescription rate for acute upper respiratory tract infections in children of $77.6 \%$ while in other countries reported rates ranged from 28.7\% (Japan) $76.2 \%$ (Albania) [30-34]. However, the Guidelines for the Clinical Application of Antibiotics in China [17], Practical Diagnosis and Treatment of Pediatric Diseases [35] and the United States CDC [28] state that acute upper respiratory tract infections are the most common com-munity-acquired infections, most commonly caused by viruses such as rhinoviruses, coronaviruses, and influenza viruses. The course of disease is generally self-limited and does not require antibiotic treatment. Treatment of symptoms if often the best form of care, especially in children, and symptoms usually subside within a few days.
Therefore, in Table 1, J06 (Acute upper respiratory infections of multiple and unspecified sites) does involve
Table 1 Distribution of antibiotic prescriptions stratified by clinical diagnosis, antibiotic group and appropriateness of use

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | I | U |
| 1. Diseases of the respiratory system |  | $\begin{aligned} & 130,371 \\ & (86.8) \end{aligned}$ | $\begin{aligned} & 84,633 \\ & (64.9) \end{aligned}$ | 24,935 (19.1) | 7689 (5.9) | 6769 (5.2) | 5360 (4.1) | 563 (0.4) | 422 (0.3) | $\begin{aligned} & 10,779 \\ & (8.3) \end{aligned}$ | $\begin{aligned} & 12,767 \\ & (9.8) \end{aligned}$ | $\begin{aligned} & 4302 \\ & (3.3) \end{aligned}$ | $\begin{aligned} & 102,523 \\ & (78.6) \end{aligned}$ |
| Upper respiratory tract infections |  | $\begin{aligned} & 99,794 \\ & (76.5) \end{aligned}$ | $\begin{aligned} & 66,995 \\ & (67.1) \end{aligned}$ | 17,718 (26.4) | 5689 (5.7) | 5038 (5.0) | 3633 (3.6) | 439 (0.4) | 282 (0.3) | $\begin{aligned} & 10,490 \\ & (10.5) \end{aligned}$ | $\begin{aligned} & 6094 \\ & (6.1) \end{aligned}$ | $\begin{aligned} & 3137 \\ & (3.1) \end{aligned}$ | $\begin{aligned} & 80,073 \\ & (80.2) \end{aligned}$ |
| J06 | Acute upper respiratory infections of multiple and unspecified sites | $\begin{aligned} & 76,478 \\ & (76.6) \end{aligned}$ | U 54,017 (70.6) | $\begin{aligned} & \mathbf{U} \\ & 12,078(22.4) \end{aligned}$ | U $4023 \text { (5.3) }$ | $\begin{aligned} & \mathbf{U} \\ & 3676(4.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 2221(2.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 220(0.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 243(0.3) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 76,478 \\ & (100.0) \end{aligned}$ |
| J03 | Acute tonsillitis | $\begin{aligned} & 17,849 \\ & (17.9) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 9257 \text { (51.9) } \end{aligned}$ | A $4597 \text { (49.7) }$ | $\begin{aligned} & \text { I } \\ & 1485 \text { (8.3) } \end{aligned}$ | A 991 (5.6) | $\begin{aligned} & \text { I } \\ & 1305 \text { (7.3) } \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 195 \text { (1.1) } \end{aligned}$ | A $19 \text { (0.1) }$ | $\begin{aligned} & 9257 \\ & (51.9) \end{aligned}$ | $\begin{aligned} & 5607 \\ & (31.4) \end{aligned}$ | $\begin{aligned} & 2985 \\ & (16.7) \end{aligned}$ | 0 (0.0) |
| $J 39$ | Other diseases of upper respiratory tract | $\begin{aligned} & 1756 \\ & (1.8) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 1356 \text { (77.2) } \end{aligned}$ | U $283 \text { (20.9) }$ | U $49 \text { (2.8) }$ | U $47 \text { (2.7) }$ | U $10 \text { (0.6) }$ | $\begin{aligned} & \text { U } \\ & 6(0.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(0.3) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 1756 \\ & (100.0) \end{aligned}$ |
| J02 | Acute pharyngitis | $\begin{aligned} & 1638 \\ & (1.6) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 1023 \text { (62.5) } \end{aligned}$ | A $335 \text { (32.7) }$ | $\begin{aligned} & \text { I } \\ & 85(5.2) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 134(8.2) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 49 \text { (3.0) } \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 8(0.5) \end{aligned}$ | A $4 \text { (0.2) }$ | $\begin{aligned} & 1023 \\ & (62.5) \end{aligned}$ | $\begin{aligned} & 473 \\ & (28.9) \end{aligned}$ | 142 (8.7) | 0 (0.0) |
| J00 | Acute nasopharyngitis [common cold] | $\begin{aligned} & 1442 \\ & (1.4) \end{aligned}$ | U $963 \text { (66.8) }$ | $\begin{aligned} & \mathbf{U} \\ & 294(30.5) \end{aligned}$ | U $17 \text { (1.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 125 \text { (8.7) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 33 \text { (2.3) } \end{aligned}$ | $4 \text { (0.3) }$ | U $6 \text { (0.4) }$ | $0(0.0)$ | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 1442 \\ & (100.0) \end{aligned}$ |
| J31 | Chronic rhinitis, nasopharyngitis and pharyngitis | 397 (0.4) | $\begin{aligned} & \mathbf{U} \\ & 255(64.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 59(23.1) \end{aligned}$ | $16 \text { (4.0) }$ | $\begin{aligned} & \mathbf{U} \\ & 51 \text { (12.8) } \end{aligned}$ | U 6 (1.5) | $\begin{aligned} & \mathbf{U} \\ & 5(1.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(1.3) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 397 \\ & (100.0) \end{aligned}$ |
| J04 | Acute laryngitis and tracheitis | 234 (0.2) | $\begin{aligned} & \mathbf{P} \\ & 124(53.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 72(58.1) \end{aligned}$ | A $14 \text { (6.0) }$ | P $14 \text { (6.0) }$ | $\begin{aligned} & \text { I } \\ & 9(3.8) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 1(0.4) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & 210 \\ & (89.7) \end{aligned}$ | 14 (6.0) | 10 (4.3) | 0 (0.0) |
| Lower respiratory tract infections |  | $\begin{aligned} & 30,577 \\ & (23.5) \end{aligned}$ | $\begin{aligned} & 17,638 \\ & (57.7) \end{aligned}$ | 7217 (40.9) | 2000 (6.5) | 1731 (5.7) | 1727 (5.6) | 124 (0.4) | 140 (0.5) | 289 (0.9) | $\begin{aligned} & 6673 \\ & (21.8) \end{aligned}$ | $\begin{aligned} & 1165 \\ & (3.8) \end{aligned}$ | $\begin{aligned} & 22,450 \\ & (73.4) \end{aligned}$ |
| J20 | Acute bronchitis | $\begin{aligned} & 19,766 \\ & (64.6) \end{aligned}$ | U 11,353 (57.4) | U 4918 (43.3) | U 1117 (5.7) | U $1162 \text { (5.9) }$ | U 1066 (5.4) | U $61 \text { (0.3) }$ | U $89 \text { (0.5) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 19,766 \\ & (100.0) \end{aligned}$ |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | I | U |
| $J 40$ | Bronchitis, not specified as acute or chronic | $\begin{aligned} & 6257 \\ & (20.5) \end{aligned}$ | A $4146 \text { (66.3) }$ | A <br> 841 (20.3) | $\begin{aligned} & \text { I } \\ & 507(8.1) \end{aligned}$ | A $258 \text { (4.1) }$ | $\begin{aligned} & \text { I } \\ & 434(6.9) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 36(0.6) \end{aligned}$ | A $35 \text { (0.6) }$ | 0 (0.0) | $\begin{aligned} & 5280 \\ & (84.4) \end{aligned}$ | $\begin{aligned} & 977 \\ & (15.6) \end{aligned}$ | 0 (0.0) |
| $J 98$ | Other respiratory disorders | $\begin{aligned} & 2122 \\ & (6.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1021 \text { (48.1) } \end{aligned}$ | U $625 \text { (61.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 283(13.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 125(5.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 51(2.4) \end{aligned}$ | U $9 \text { (0.4) }$ | $\begin{aligned} & \mathbf{U} \\ & 8(0.4) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 2122 \\ & (100.0) \end{aligned}$ |
| $J 18$ | Pneumonia, organism unspecified | $\begin{aligned} & 1554 \\ & (5.1) \end{aligned}$ | A $566 \text { (36.4) }$ | A $667 \text { (42.9) }$ | $\begin{aligned} & \text { l } \\ & 51 \text { (3.3) } \end{aligned}$ | A $142 \text { (9.1) }$ | $\begin{aligned} & \text { I } \\ & 117(7.5) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 8(0.5) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 3(0.2) \end{aligned}$ | 0 (0.0) | $\begin{aligned} & 1378 \\ & (88.7) \end{aligned}$ | $\begin{aligned} & 176 \\ & (11.3) \end{aligned}$ | 0 (0.0) |
| J21 | Acute bronchiolitis | 562 (1.8) | U $314 \text { (55.9) }$ | U $119 \text { (37.9) }$ | $\begin{aligned} & \text { U } \\ & 27(4.8) \end{aligned}$ | U $43 \text { (7.7) }$ | U $47 \text { (8.4) }$ | U $10(1.8)$ | $\begin{aligned} & \mathbf{U} \\ & 2(0.4) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 562 \\ & (100.0) \end{aligned}$ |
| J22 | Unspecified acute lower respiratory infection | 316 (1.0) | $\begin{aligned} & \mathbf{P} \\ & 238(75.3) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 47(14.9) \end{aligned}$ | A $15 \text { (4.7) }$ | $\begin{aligned} & \mathbf{P} \\ & 1(0.3) \end{aligned}$ | $\begin{aligned} & \mathbf{I} \\ & 12(3.8) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 3(0.9) \end{aligned}$ | $\begin{aligned} & 289 \\ & (91.5) \end{aligned}$ | 15 (4.7) | 12 (3.8) | 0 (0.0) |
| 2. Diseases of the digestive system |  | $\begin{aligned} & 9047 \\ & (6.0) \end{aligned}$ | 4839 (53.5) | 1188 (13.1) | 403 (4.5) | 307 (3.4) | 1280 (14.1) | 631 (7.0) | 399 (4.4) | $\begin{aligned} & 2000 \\ & (22.1) \end{aligned}$ | $\begin{aligned} & 1218 \\ & (13.5) \end{aligned}$ | 388 (4.3) | $\begin{aligned} & 5441 \\ & (60.1) \end{aligned}$ |
| K52 | Other noninfective gastroenteritis and colitis | $\begin{aligned} & 4360 \\ & (48.2) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 2089 \text { (47.9) } \end{aligned}$ | U $554 \text { (12.7) }$ | $\begin{aligned} & \text { U } \\ & 213 \text { (4.9) } \end{aligned}$ | U $36 \text { (0.8) }$ | $\begin{aligned} & \text { U } \\ & 1006 \text { (23.1) } \end{aligned}$ | U $140 \text { (3.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 322 \text { (7.4) } \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 4360 \\ & (100.0) \end{aligned}$ |
| K05 | Gingivitis and periodontal diseases | $\begin{aligned} & 1365 \\ & (15.1) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 730(53.5) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 200(14.7) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 67(4.9) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 81 \text { (5.9) } \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 11(0.8) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 268(19.6) \end{aligned}$ | A <br> 8 (0.6) | $\begin{aligned} & 998 \\ & (73.1) \end{aligned}$ | $\begin{aligned} & 289 \\ & (21.2) \end{aligned}$ | 78 (5.7) | 0 (0.0) |
| K29 | Gastritis and duodenitis | $\begin{aligned} & 1177 \\ & (13.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 789(67.0) \end{aligned}$ | $96 \text { (8.2) }$ | $\begin{aligned} & \text { I } \\ & 55(4.7) \end{aligned}$ | A <br> 73 (6.2) | $\begin{aligned} & \text { I } \\ & 70(5.9) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 58(4.9) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 36(3.1) \end{aligned}$ | $\begin{aligned} & 789 \\ & (67.0) \end{aligned}$ | $\begin{aligned} & 167 \\ & (14.2) \end{aligned}$ | $\begin{aligned} & 221 \\ & (18.8) \end{aligned}$ | 0 (0.0) |
| K30 | Functional dyspepsia | 776 (8.6) | U $488 \text { (62.9) }$ | $\begin{aligned} & \mathbf{U} \\ & 106 \text { (13.7) } \end{aligned}$ | U $5 \text { (1.9) }$ | U <br> 22 (2.8) | $\begin{aligned} & \mathbf{U} \\ & 121 \text { (15.6) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | U $24 \text { (3.1) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 776 \\ & (100.0) \end{aligned}$ |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | 1 | U |
| K12 | Stomatitis and related lesions | 686 (7.6) | $\begin{aligned} & \text { A } \\ & 378(55.1) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 118(17.2) \end{aligned}$ | $\begin{aligned} & 1 \\ & 32(4.7) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 49 \text { (7.1) } \end{aligned}$ | $\begin{aligned} & 1 \\ & 52(7.6) \end{aligned}$ | A $55 \text { (8.0) }$ | $\begin{aligned} & \mathbf{I} \\ & 2(0.3) \end{aligned}$ | 0 (0.0) | $\begin{aligned} & 600 \\ & (87.5) \end{aligned}$ | 86 (12.5) | 0 (0.0) |
| K04 | Diseases of pulp and periapical tissues | 218 (2.4) | $\begin{aligned} & \text { P } \\ & 103 \text { (47.2) } \end{aligned}$ | A $30 \text { (13.8) }$ | $\begin{aligned} & \text { A } \\ & 3(1.4) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 23(10.6) \end{aligned}$ | $\begin{aligned} & \mathbf{I} \\ & 1(0.5) \end{aligned}$ | $58(26.6)$ | A 0 (0.0) | $\begin{aligned} & 161 \\ & (73.9) \end{aligned}$ | 56 (25.7) | 1 (0.5) | 0 (0.0) |
| K13 | Other <br> diseases <br> of lip <br> and oral <br> mucosa | 85 (0.9) | $\begin{aligned} & \text { U } \\ & 51 \text { (60.0) } \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 17(20.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(5.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 6(7.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 4(4.7) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 2(2.4) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 85 (100.0) |
| K81 | Cholecystitis | 85 (0.9) | A <br> 62 (72.9) | $\begin{aligned} & \text { P } \\ & 12(14.1) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0 \text { (0.0) } \end{aligned}$ | $\begin{aligned} & \mathbf{I} \\ & 2(2.4) \end{aligned}$ | A $0 \text { (0.0) }$ | A $8 \text { (9.4) }$ | $\begin{aligned} & \text { A } \\ & 1(1.2) \end{aligned}$ | 12 (14.1) | 71 (83.5) | 2 (2.4) | 0 (0.0) |
| K08 | Other <br> disorders of teeth and supporting structures | 76 (0.8) | $\begin{aligned} & \text { U } \\ & 46(60.5) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(6.6) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 2(2.6) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 9(11.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 13(17.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1(1.3) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 76 (100.0) |
| K35 | Acute appendicitis | 50 (0.6) | $\begin{aligned} & \text { A } \\ & 11(22.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 15(30.0) \end{aligned}$ | A 5 (10.0) | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 1(2.0) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 18(36.0) \end{aligned}$ | A 0 (0.0) | 15 (30.0) | 35 (70.0) | 0 (0.0) | 0 (0.0) |
| K14 | Diseases of tongue | 48 (0.5) | $\begin{aligned} & \text { U } \\ & 32(66.7) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(6.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1(2.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(10.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 7(14.6) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 48 (100.0) |
| K59 | Other functional intestinal disorders | 34 (0.4) | $\begin{aligned} & \text { U } \\ & 18(52.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(8.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 11(32.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U}(5.9) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 34 (100.0) |
| K11 | Diseases of salivary glands | 31 (0.3) | $\begin{aligned} & \text { U } \\ & 14(45.2) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 14(45.2) \end{aligned}$ | $\begin{aligned} & \mathbf{u} \\ & 2(6.5) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | u $1 \text { (3.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 31 (100.0) |
| K92 | Other diseases of digestive system | 31 (0.3) | $\begin{aligned} & \mathbf{U}_{21}(67.7) \end{aligned}$ | U $6(19.4)$ | $\begin{aligned} & \mathbf{U} \\ & 3(9.7) \end{aligned}$ | U $1 \text { (3.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 31 (100.0) |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | I | U |
| K36 | Other appendicitis | 25 (0.3) | $\begin{aligned} & \mathbf{P} \\ & 7(28.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 9(36.0) \end{aligned}$ | A $0 \text { (0.0) }$ | A $0(0.0)$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 8(32.0) \end{aligned}$ | P $1 \text { (4.0) }$ | $\begin{aligned} & 25 \\ & (100.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 3. Diseases of the skin and subcutaneous tissue |  | $\begin{aligned} & 3220 \\ & (2.1) \end{aligned}$ | 1638 (50.9) | 800 (24.8) | 297 (9.2) | 79 (2.5) | 64 (2.0) | 321 (10.0) | 21 (0.7) | $\begin{aligned} & 350 \\ & (10.9) \end{aligned}$ | 18 (0.6) | 60 (1.9) | $\begin{aligned} & 2792 \\ & (86.7) \end{aligned}$ |
| L08 | Other local infections of skin and subcutaneous tissue | $\begin{aligned} & 1556 \\ & (48.3) \end{aligned}$ | U $727 \text { (46.7) }$ | U 434 (27.9) | U $87 \text { (5.6) }$ | U 25 (1.6) | $\begin{aligned} & \mathbf{U} \\ & 34 \text { (2.2) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 231(14.8) \end{aligned}$ | U 18 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 1556 \\ & (100.0) \end{aligned}$ |
| L23 | Allergic contact dermatitis | $\begin{aligned} & 556 \\ & (17.3) \end{aligned}$ | U $289 \text { (52.0) }$ | $\begin{aligned} & \text { U } \\ & 86 \text { (15.5) } \end{aligned}$ | U $133 \text { (23.9) }$ | $\begin{aligned} & \mathbf{U} \\ & 12(2.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 23(4.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 13(2.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 556 \\ & (100.0) \end{aligned}$ |
| L04 | Acute lymphadenitis | $\begin{aligned} & 443 \\ & (13.8) \end{aligned}$ | U $266 \text { (60.0) }$ | U $116 \text { (26.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 22 \text { (5.0) } \end{aligned}$ | $22 \text { (5.0) }$ | $\begin{aligned} & \mathbf{U} \\ & 3(0.7) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 14 \text { (3.2) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 443 \\ & (100.0) \end{aligned}$ |
| L03 | Cellulitis | 257 (8.0) | $\begin{aligned} & \mathbf{P} \\ & 153 \text { (59.5) } \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 61 \text { (23.7) } \end{aligned}$ | A $8 \text { (3.1) }$ | A $6 \text { (2.3) }$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 29 \text { (11.3) } \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & 214 \\ & (83.3) \end{aligned}$ | 14 (5.4) | 29 (11.3) | 0 (0.0) |
| L02 | Cutaneous abscess, furuncle and carbuncle | 159 (4.9) | $\begin{aligned} & \mathbf{P} \\ & 79(49.7) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 37(23.3) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 9(5.7) \end{aligned}$ | A $2(1.3)$ | $\begin{aligned} & \text { I } \\ & 1(0.6) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 29 \text { (18.2) } \end{aligned}$ | A $2(1.3)$ | $\begin{aligned} & 125 \\ & (78.6) \end{aligned}$ | 4 (2.5) | 30 (18.9) | 0 (0.0) |
| L30 | Other dermatitis | 159 (4.9) | $\begin{aligned} & \mathbf{U} \\ & 78 \text { (49.1) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 45(28.3) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 28 \text { (17.6) } \end{aligned}$ | U $5 \text { (3.1) }$ | U $1 \text { (0.6) }$ | U $1 \text { (0.6) }$ | U $1 \text { (0.6) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 159 \\ & (100.0) \end{aligned}$ |
| L24 | Irritant contact dermatitis | 32 (1.0) | $\begin{aligned} & \mathbf{U} \\ & 15(46.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 8(25.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 6(18.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 2(6.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1 \text { (3.1) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 32 (100.0) |
| L50 | Urticaria | 29 (0.9) | $\begin{aligned} & \mathbf{U} \\ & 16(55.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 8 \text { (27.6) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(10.3) \end{aligned}$ | U $0 \text { (0.0) }$ | U $2 \text { (6.9) }$ | U $0(0.0)$ | U $0 \text { (0.0) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 29 (100.0) |
| L70 | Acne | 17 (0.5) | $\begin{aligned} & \mathbf{U} \\ & 7(41.2) \end{aligned}$ | U $2 \text { (11.8) }$ | U $1 \text { (5.9) }$ | $\begin{aligned} & \mathbf{U} \\ & 5(29.4) \end{aligned}$ | U $0 \text { (0.0) }$ | U $2(11.8)$ | U $0 \text { (0.0) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 17 (100.0) |
| L01 | Impetigo | 12 (0.4) | $\begin{aligned} & \mathbf{P} \\ & 8(66.7) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 3(25.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 0(0.0) \end{aligned}$ | A $0 \text { (0.0) }$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 1 \text { (8.3) } \end{aligned}$ | A $0 \text { (0.0) }$ | 11 (91.7) | $0(0.0)$ | 1 (8.3) | 0 (0.0) |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | I | U |
| 4. Sympt and abn cal and findings where cl | ms, signs rmal cliniboratory ot elsessified | $\begin{aligned} & 2609 \\ & (1.7) \end{aligned}$ | 1590 (60.9) | 376 (14.4) | 145 (5.6) | 94 (3.6) | 257 (9.9) | 59 (2.3) | 88 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 2609 \\ & (100.0) \end{aligned}$ |
| R10 | Abdominal and pelvic pain | $\begin{aligned} & 1827 \\ & (70.0) \end{aligned}$ | U $1132 \text { (62.0) }$ | $\begin{aligned} & \mathbf{U} \\ & 260(14.2) \end{aligned}$ | $58 \text { (3.2) }$ | U $47 \text { (2.6) }$ | U <br> 204 (11.2) | $46 \text { (2.5) }$ | $\begin{aligned} & \mathbf{U} \\ & 80(4.4) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 1827 \\ & (100.0) \end{aligned}$ |
| R05 | Cough | 161 (6.2) | U <br> 91 (56.5) | $\begin{aligned} & \mathbf{U} \\ & 18 \text { (11.2) } \end{aligned}$ | U $12 \text { (7.5) }$ | $\begin{aligned} & \mathbf{U} \\ & 7(4.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 29(18.0) \end{aligned}$ | U $0(0.0)$ | U $4 \text { (2.5) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 161 \\ & (100.0) \end{aligned}$ |
| R59 | Enlarged lymph nodes | 146 (5.6) | $\begin{aligned} & \mathbf{U} \\ & 104 \text { (71.2) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 20 \text { (13.7) } \end{aligned}$ | U $9 \text { (6.2) }$ | $\begin{aligned} & \mathbf{U} \\ & 5(3.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 4(2.7) \end{aligned}$ | U $4 \text { (2.7) }$ | U $0 \text { (0.0) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 146 \\ & (100.0) \end{aligned}$ |
| R50 | Fever of other and unknown origin | 140 (5.4) | $\begin{aligned} & \text { U } \\ & 65(46.4) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 19 \text { (13.6) } \end{aligned}$ | U $47 \text { (33.6) }$ | $\begin{aligned} & \text { U } \\ & 2(1.4) \end{aligned}$ | U $4 \text { (2.9) }$ | U $1 \text { (0.7) }$ | U $2 \text { (1.4) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 140 \\ & (100.0) \end{aligned}$ |
| R04 | Haemorrhage from respiratory passages | 93 (3.6) | $\begin{aligned} & \text { U } \\ & 60(64.5) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 13 \text { (14.0) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 7(7.5) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 12(12.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | U $1 \text { (1.1) }$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 93 (100.0) |
| R07 | Pain in throat and chest | 70 (2.7) | $\begin{aligned} & \mathbf{U} \\ & 51 \text { (72.9) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 8(11.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3 \text { (4.3) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(7.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3 \text { (4.3) } \end{aligned}$ | U 0 (0.0) | U $0 \text { (0.0) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 70 (100.0) |
| R51 | Headache | 63 (2.4) | $\begin{aligned} & \mathbf{U} \\ & 25(39.7) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 13 \text { (20.6) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 8(12.7) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 12(19.0) \end{aligned}$ | U $0 \text { (0.0) }$ | $3(4.8)$ | U $2 \text { (3.2) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 63 (100.0) |
| R22 | Localized swelling, mass and lump of skin and subcutaneous tissue | 42 (1.6) | $\begin{aligned} & \text { U } \\ & 27 \text { (64.3) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 12(28.6) \end{aligned}$ | U $0(0.0)$ | U $1 \text { (2.4) }$ | U $0(0.0)$ | $\begin{aligned} & \mathbf{U} \\ & 2(4.8) \end{aligned}$ | U $0(0.0)$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 42 (100.0) |
| R21 | Rash and other nonspecific skin eruption | 38 (1.5) | $\begin{aligned} & \mathbf{U} \\ & 21(55.3) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 10(26.3) \end{aligned}$ | U $1 \text { (2.6) }$ | $\begin{aligned} & \mathbf{U} \\ & 3(7.9) \end{aligned}$ | U $1 \text { (2.6) }$ | $\begin{aligned} & \mathbf{U} \\ & 2(5.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 38 (100.0) |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | 1 | U |
| R11 | Nausea <br> and vomiting | 29 (1.1) | $\begin{aligned} & \text { U } \\ & 14(48.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(10.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 12(41.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 29 (100.0) |
| 5. Injury, poisoning and certain other consequences of external causes |  | $\begin{aligned} & 1685 \\ & (1.1) \end{aligned}$ | 1127 (66.9) | 315 (18.7) | 77 (4.6) | 37 (2.2) | 21 (1.2) | 100 (5.9) | 8 (0.5) | $\begin{aligned} & 723 \\ & (42.9) \end{aligned}$ | 73 (4.3) | 15 (0.9) | 874 (51.9) |
| T14 | Injury of unspecified body region | $\begin{aligned} & 748 \\ & (44.4) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 482(64.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 120(16.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 39 \text { (5.2) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 20(2.7) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 21(2.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 61 \text { (8.2) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 5(0.7) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 748 \\ & (100.0) \end{aligned}$ |
| S01 | Open wound of head | $\begin{aligned} & 576 \\ & (34.2) \end{aligned}$ | $406 \text { (70.5) }$ | $\begin{aligned} & \mathbf{P} \\ & 114(19.8) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 22(3.8) \end{aligned}$ | $\begin{aligned} & 10(1.7) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 24(4.2) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & 520 \\ & (90.3) \end{aligned}$ | 46 (8.0) | 10 (1.7) | 0 (0.0) |
| 500 | Superficial injury of head | $\begin{aligned} & 177 \\ & (10.5) \end{aligned}$ | $\begin{aligned} & \text { P } \\ & 137 \text { (77.4) } \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 27(15.3) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 6(3.4) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 3(1.7) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0 \text { (0.0) } \end{aligned}$ | A $4(2.3)$ | A 0 (0.0) | $\begin{aligned} & 164 \\ & (92.7) \end{aligned}$ | 13 (7.3) | 0 (0.0) | 0 (0.0) |
| T11 | Other injuries of upper limb, level unspecified | 126 (7.5) | $\mathbf{U}_{63(50.0)}$ | $\begin{aligned} & \mathbf{U} \\ & 40(31.7) \end{aligned}$ | $\begin{aligned} & \text { U (7.9) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 4(3.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 6(4.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(2.4) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 126 \\ & (100.0) \end{aligned}$ |
| T13 | Other injuries of lower limb, level unspecified | 58 (3.4) | $39 \text { (67.2) }$ | A $14 \text { (24.1) }$ | A $0(0.0)$ | $\begin{aligned} & \text { A } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0 \text { (0.0) } \end{aligned}$ | $\begin{aligned} & 1 \\ & 5(8.6) \end{aligned}$ | A $0 \text { (0.0) }$ | 39 (67.2) | 14 (24.1) | 5 (8.6) | 0 (0.0) |
| 6. Diseases of the genitourinary system |  | 891 (0.6) | 376 (42.2) | 232 (26.0) | 45 (5.1) | 30 (3.4) | 13 (1.5) | 108 (12.1) | 87 (9.8) | $\begin{aligned} & 202 \\ & (22.7) \end{aligned}$ | $\begin{aligned} & 151 \\ & (16.9) \end{aligned}$ | 41 (4.6) | 497 (55.8) |
| N39 | Other disorders of urinary system | $\begin{aligned} & 359 \\ & (40.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 155(43.2) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 101 \text { (28.1) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & \sigma(1.7) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 11 \text { (3.1) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 10(2.8) \end{aligned}$ | $\begin{aligned} & \text { U } 26 \text { (7.2) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 50(13.9) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 359 \\ & (100.0) \end{aligned}$ |
| N34 | Urethritis and urethral syndrome | $\begin{aligned} & 194 \\ & (21.8) \end{aligned}$ | $103 \text { (53.1) }$ | $\begin{aligned} & \text { P } \\ & 48(24.7) \end{aligned}$ | $\begin{aligned} & 1 \\ & 1(0.5) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 9(4.6) \end{aligned}$ | $\begin{aligned} & 1 \\ & 2(1.0) \end{aligned}$ | $\begin{aligned} & 1 \\ & 9(4.6) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 22(11.3) \end{aligned}$ | $\begin{aligned} & 160 \\ & (82.5) \end{aligned}$ | 22 (11.3) | 12 (6.2) | 0 (0.0) |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | I | U |
| N48 | Other disorders of penis | $\begin{aligned} & 138 \\ & (15.5) \end{aligned}$ | U $66 \text { (47.8) }$ | $\begin{aligned} & \text { U } \\ & 37 \text { (26.8) } \end{aligned}$ | U $10 \text { (7.2) }$ | U $6(4.3)$ | $\begin{aligned} & \mathbf{U} \\ & 1(0.7) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 16 \text { (11.6) } \end{aligned}$ | U $2 \text { (1.4) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 138 \\ & (100.0) \end{aligned}$ |
| N73 | Other female pelvic inflammatory diseases | $\begin{aligned} & 116 \\ & (13.0) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 34(29.3) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 24(20.7) \end{aligned}$ | $8 \text { (6.9) }$ | $\begin{aligned} & \text { A } \\ & 3(2.6) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 36(31.0) \end{aligned}$ | A <br> 11 (9.5) | 24 (20.7) | 84 (72.4) | 8 (6.9) | 0 (0.0) |
| N47 | Redundant prepuce, phimosis and paraphimosis | 84 (9.4) | $\begin{aligned} & \mathbf{P} \\ & 18(21.4) \end{aligned}$ | A $22 \text { (26.2) }$ | A $20(23.8)$ | A $1 \text { (1.2) }$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | I $21 \text { (25.0) }$ | $\begin{aligned} & \text { A } \\ & 2(2.4) \end{aligned}$ | 18 (21.4) | 45 (53.6) | 21 (25.0) | 0 (0.0) |
| 7. Diseases of the circulatory system |  | 669 (0.4) | 416 (62.2) | 150 (22.4) | 33 (4.9) | 29 (4.3) | 14 (2.1) | 21 (3.1) | 6 (0.9) | 20 (3.0) | 1 (0.1) | 8 (1.2) | 640 (95.7) |
| 188 | Nonspecific lymphadenitis | $\begin{aligned} & 589 \\ & (88.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 364(61.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 138(23.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 30(5.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 27 \text { (4.6) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 14(2.4) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 15(2.5) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1(0.2) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 589 \\ & (100.0) \end{aligned}$ |
| 184 | Haemorrhoids | 42 (6.3) | U $26 \text { (61.9) }$ | U $4 \text { (9.5) }$ | $\begin{aligned} & \mathbf{U} \\ & 2(4.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 2(4.8) \end{aligned}$ | U $0 \text { (0.0) }$ | U $5(11.9)$ | $\begin{aligned} & \mathbf{U} \\ & 3 \text { (7.1) } \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 42 (100.0) |
| 100 | Rheumatic fever without mention of heart involvement | 21 (3.1) | $\begin{aligned} & \mathbf{P} \\ & 18(85.7) \end{aligned}$ | A $1 \text { (4.8) }$ | $1 \text { (4.8) }$ | A $0(0.0)$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I (4.8) } \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | 18 (85.7) | 1 (4.8) | 2 (9.5) | 0 (0.0) |
| 167 | Other cerebrovascular diseases | $9(1.3)$ | U $6 \text { (66.7) }$ | $\begin{aligned} & \mathbf{U} \\ & 2 \text { (22.2) } \end{aligned}$ | U $0(0.0)$ | U $0(0.0)$ | U $0 \text { (0.0) }$ | U $0 \text { (0.0) }$ | U $1 \text { (11.1) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (100.0) |
| 140 | Acute myocarditis | 8 (1.2) | $\begin{aligned} & \mathbf{P} \\ & 2(25.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 5(62.5) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{I} \\ & 1(12.5) \end{aligned}$ | 2 (25.0) | 0 (0.0) | 6 (75.0) | 0 (0.0) |
| 8. Diseases of the ear and mastoid process |  | 603 (0.4) | 384 (63.7) | 127 (21.1) | 16 (2.7) | 33 (5.5) | $9(1.5)$ | 29 (4.8) | 5 (0.8) | $\begin{aligned} & 410 \\ & (68.0) \end{aligned}$ | 80 (13.3) | 37 (6.1) | 76 (12.6) |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | 1 | U |
| H66 | Suppurative and unspecified otitis media | $\begin{aligned} & 468 \\ & (77.6) \end{aligned}$ | $\begin{aligned} & \text { P } \\ & 290(62.0) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 105 \text { (22.4) } \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 11(2.4) \end{aligned}$ | A $23 \text { (4.9) }$ | $\begin{aligned} & \text { I } \\ & 7(1.5) \end{aligned}$ | $\begin{aligned} & 1 \\ & 27 \text { (5.8) } \end{aligned}$ | A 5 (1.1) | $\begin{aligned} & 395 \\ & (84.4) \end{aligned}$ | 39 (8.3) | 34 (7.3) | 0 (0.0) |
| H65 | Nonsuppurative otitis media | 44 (7.3) | $\begin{aligned} & \mathbf{U} \\ & 32(72.7) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 6 \text { (13.6) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(6.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(6.8) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 44 (100.0) |
| H60 | Otitis externa | 43 (7.1) | $\begin{aligned} & \text { A } \\ & 28(65.1) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 9(20.9) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 1(2.3) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 3(7.0) \end{aligned}$ | $\begin{aligned} & \mathbf{I} \\ & 2(4.7) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 0(0.0) \end{aligned}$ | 3 (7.0) | 38 (88.4) | $2(4.7)$ | 0 (0.0) |
| H61 | Other disorders of external ear | 32 (5.3) | $\begin{aligned} & \mathbf{U} \\ & 25(78.1) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 4(12.5) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{u} \\ & 2(6.3) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1(3.1) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 32 (100.0) |
| H70 | Mastoidi- <br> tis and related conditions | 16 (2.7) | $\begin{aligned} & \mathbf{P} \\ & 9(56.3) \end{aligned}$ | $3(18.8)$ | A $1 \text { (6.3) }$ | $\begin{aligned} & \text { A } \\ & 2(12.5) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0 \text { (0.0) } \end{aligned}$ | $\begin{aligned} & 1(6.3) \end{aligned}$ | A <br> 0 (0.0) | 12 (75.0) | 3 (18.8) | 1 (6.3) | 0 (0.0) |
| 9. Certain infectious and parasitic diseases |  | 590 (0.4) | 329 (55.8) | 73 (12.4) | 40 (6.8) | 4 (0.7) | 120 (20.3) | $9(1.5)$ | 15 (2.5) | 1 (0.2) | $\begin{aligned} & 185 \\ & (31.4) \end{aligned}$ | 78 (13.2) | 326 (55.3) |
| A09 | Other gastroenteritis and colitis of infectious and unspecified origin | $\begin{aligned} & 207 \\ & (35.1) \end{aligned}$ | A $145 \text { (70.0) }$ | $\begin{aligned} & 15(7.2) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{I} \\ & 2(1.0) \end{aligned}$ | $35 \text { (16.9) }$ | $\begin{aligned} & \mathbf{I} \\ & 2(1.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 8 \text { (3.9) } \end{aligned}$ | 0 (0.0) | $\begin{aligned} & 145 \\ & (70.0) \end{aligned}$ | 62 (30.0) | 0 (0.0) |
| B00 | Herpesvi- <br> ral [herpes <br> simplex] <br> infections | $\begin{aligned} & 137 \\ & (23.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 59(43.1) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 25(18.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 39(28.5) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 11 \text { (8.0) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 3(2.2) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 137 \\ & (100.0) \end{aligned}$ |
| A08 | Viral and other specified intestinal infections | $\begin{aligned} & 101 \\ & (17.1) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 40(39.6) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 6(5.9) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 1(1.0) \end{aligned}$ | $\begin{aligned} & \text { U } \\ & 44(43.6) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 4(4.0) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 6(5.9) \end{aligned}$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | $\begin{aligned} & 101 \\ & (100.0) \end{aligned}$ |

Table 1 (continued)

| ICD 10 | Disease | Total | Penicillins | Cephalosporins | Lincosamides | Macrolides | Aminoglycosides | Nitroimidazoles | Quinolones | Appropriate use |  | Inappropriate use |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |  |  | P | A | I | U |
| B08 | Other viral infections characterized by skin and mucous membrane lesions, not elsewhere classified | 88 (14.9) | $\begin{aligned} & \mathbf{U} \\ & 52(59.1) \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 21(23.9) \end{aligned}$ | U $0(0.0)$ | U $0 \text { (0.0) }$ | $\begin{aligned} & \mathbf{U} \\ & 15(17.0) \end{aligned}$ | U $0(0.0)$ | U $0(0.0)$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 88 (100.0) |
| A04 | Other bacterial intestinal infections | 57 (9.7) | A $33 \text { (57.9) }$ | A $6 \text { (10.5) }$ | $\begin{aligned} & \text { I } \\ & 1.8) \end{aligned}$ | A $1 \text { (1.8) }$ | $\begin{aligned} & \text { I } \\ & 15 \text { (26.3) } \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 0(0.0) \end{aligned}$ | P <br> 1 (1.8) | 1 (1.8) | 40 (70.2) | 16 (28.1) | 0 (0.0) |
| 10.Diseases of the eye and adnexa |  | 448 (0.3) | 272 (60.7) | 76 (17.0) | 18 (4.0) | 64 (14.3) | 3 (0.7) | 12 (2.7) | 3 (0.7) | 37 (8.3) | $\begin{aligned} & 207 \\ & (46.2) \end{aligned}$ | $\begin{aligned} & 166 \\ & (37.1) \end{aligned}$ | 38 (8.5) |
| H16 | Keratitis | $\begin{aligned} & 135 \\ & (30.1) \end{aligned}$ | I $85 \text { (63.0) }$ | I $27 \text { (20.0) }$ | $\begin{aligned} & \text { I } \\ & 6(4.4) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 13 \text { (9.6) } \end{aligned}$ | A $1 \text { (0.7) }$ | $\begin{aligned} & \text { I } \\ & 1(0.7) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 2(1.5) \end{aligned}$ | 2 (1.5) | 1 (0.7) | $\begin{aligned} & 132 \\ & (97.8) \end{aligned}$ | 0 (0.0) |
| H01 | Other inflammation of eyelid | $\begin{aligned} & 128 \\ & (28.6) \end{aligned}$ | A $86 \text { (67.2) }$ | $\begin{aligned} & \text { I } \\ & 23 \text { (18.0) } \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 3(2.3) \end{aligned}$ | $\begin{aligned} & \text { A } \\ & 13(10.2) \end{aligned}$ | A $1 \text { (0.8) }$ | $\begin{aligned} & \text { I } \\ & 2(1.6) \end{aligned}$ | A 0 (0.0) | 0 (0.0) | $\begin{aligned} & 103 \\ & (80.5) \end{aligned}$ | 25 (19.5) | $0(0.0)$ |
| HOO | Hordeolum and chalazion | 88 (19.6) | A $52 \text { (59.1) }$ | A <br> 14 (15.9) | $\begin{aligned} & \mathbf{P} \\ & 3(3.4) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 11(12.5) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 0(0.0) \end{aligned}$ | $\begin{aligned} & \text { I } \\ & 8(9.1) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 0(0.0) \end{aligned}$ | 14 (15.9) | 66 (75.0) | 8 (9.1) | 0 (0.0) |
| H10 | Conjunctivitis | 59 (13.2) | A $29 \text { (49.2) }$ | A $8 \text { (13.6) }$ | $\begin{aligned} & \mathbf{P} \\ & 5(8.5) \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 14 \text { (23.7) } \end{aligned}$ | $\begin{aligned} & \mathbf{P} \\ & 1(1.7) \end{aligned}$ | $1 \text { (1.7) }$ | $\begin{aligned} & \mathbf{P} \\ & 1(1.7) \end{aligned}$ | 21 (35.6) | 37 (62.7) | 1 (1.7) | 0 (0.0) |
| $\mathrm{H} 02$ | Other disorders of eyelid | 38 (8.5) | $\begin{aligned} & \mathbf{U} \\ & 20 \text { (52.6) } \end{aligned}$ | $\begin{aligned} & \mathbf{U} \\ & 4(10.5) \end{aligned}$ | U $1 \text { (2.6) }$ | $\begin{aligned} & \text { U } \\ & 13(34.2) \end{aligned}$ | U $0 \text { (0.0) }$ | U $0(0.0)$ | U $0 \text { (0.0) }$ | 0 (0.0) | 0 (0.0) | 0 (0.0) | 38 (100.0) |
| Total prescriptions |  | 150,133 | $\begin{aligned} & 95,604 \\ & (63.7) \end{aligned}$ | 28,272 (18.8) | 8763 (5.8) | 7446 (5.0) | 7141 (4.8) | 1853 (1.2) | 1054 (0.7) | $\begin{aligned} & 14,522 \\ & (9.7) \end{aligned}$ | $\begin{aligned} & 14,700 \\ & (9.8) \end{aligned}$ | $\begin{aligned} & 5095 \\ & (3.4) \end{aligned}$ | $\begin{aligned} & 115,816 \\ & (77.1) \end{aligned}$ |

Numbers in the table are frequency (\%)
P: Preferred medication
A: Antibiotic can be used or substituted
I: Incorrect spectrum of antibiotics
U: Unnecessary use

Table 2 Factors associated with inappropriate use of antibiotics on bivariate analysis

| Characteristic | Total, N (\%) | Appropriate use, n (\%) |  | Inappropriate use, n (\%) |  |  | Chi-square test |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Preferred medication | Antibiotic can be used or substituted | Combined use of antibiotics | Incorrect spectrum of antibiotics | Unnecessary use | $\mathrm{X}^{2}$ | $P$ value |
| Total | 137,284 | 12,991 (9.5) | 12,036 (8.8) | 3361 (2.4) | 3308 (2.4) | 105,588 (76.9) |  |  |
| Physician-related factors |  |  |  |  |  |  |  |  |
| Sex |  |  |  |  |  |  | 256.80 | < 0.001 |
| Female | 43,202 (31.5) | 4642 (10.7) | 3247 (7.5) | 1041 (2.4) | 887 (2.1) | 33,385 (77.3) |  |  |
| Male | 94,082 (68.5) | 8349 (8.9) | 8789 (9.3) | 2320 (2.5) | 2421 (2.6) | 72,203 (76.7) |  |  |
| Age group (years) |  |  |  |  |  |  | 523.01 | $<0.001$ |
| 23-32 | 48,348 (35.2) | 5042 (10.4) | 4043 (8.4) | 1418 (2.9) | 1126 (2.3) | 36,719 (75.9) |  |  |
| 33-40 | 46,024 (33.5) | 4390 (9.5) | 3510 (7.6) | 930 (2.0) | 921 (2.0) | 36,273 (78.8) |  |  |
| 41-65 | 42,912 (31.3) | 3559 (8.3) | 4483 (10.4) | 1013 (2.4) | 1261 (2.9) | 32,596 (76.0) |  |  |
| Professional title |  |  |  |  |  |  | 146.91 | $<0.001$ |
| Associate chief physician | 5601 (4.1) | 646 (11.5) | 535 (9.6) | 82 (1.5) | 163 (2.9) | 4175 (74.5) |  |  |
| Attending physician | 16,559 (12.1) | 1496 (9.0) | 1284 (7.8) | 291 (1.8) | 353 (2.1) | 13,135 (79.3) |  |  |
| Resident physician | 115,124 (83.9) | 10,849 (9.4) | 10,217 (8.9) | 2988 (2.6) | 2792 (2.4) | 88,278 (76.7) |  |  |
| Education |  |  |  |  |  |  | 447.37 | $<0.001$ |
| College | 57,121 (41.6) | 5907 (10.3) | 4697 (8.2) | 1231 (2.2) | 1031 (1.8) | 44,255 (77.5) |  |  |
| Junior college | 57,979 (42.2) | 5333 (9.2) | 5607 (9.7) | 1549 (2.7) | 1518 (2.6) | 43,972 (75.8) |  |  |
| Technical secondary school | 22,184 (16.2) | 1751 (7.9) | 1732 (7.8) | 581 (2.6) | 759 (3.4) | 17,361 (78.3) |  |  |
| Work duration (years) |  |  |  |  |  |  | 2466.86 | < 0.001 |
| $\leq 5$ | 30,322 (22.1) | 3046 (10.0) | 2925 (9.6) | 1014 (3.3) | 961 (3.2) | 22,376 (73.8) |  |  |
| 6-10 | 50,214 (36.6) | 4906 (9.8) | 2966 (5.9) | 903 (1.8) | 602 (1.2) | 40,837 (81.3) |  |  |
| 11-20 | 22,207 (16.2) | 2225 (10.0) | 2181 (9.8) | 579 (2.6) | 592 (2.7) | 16,630 (74.9) |  |  |
| 21-30 | 21,077 (15.4) | 1782 (8.5) | 2338 (11.1) | 489 (2.3) | 864 (4.1) | 15,604 (74.0) |  |  |
| 31-39 | 10,364 (7.5) | 840 (8.1) | 1521 (14.7) | 354 (3.4) | 236 (2.3) | 7413 (71.5) |  |  |
| $\geq 40$ | 3100 (2.3) | 192 (6.2) | 105 (3.4) | 22 (0.7) | 53 (1.7) | 2728 (88.0) |  |  |
| Patient-related factors |  |  |  |  |  |  |  |  |
| Sex |  |  |  |  |  |  | 88.17 | $<0.001$ |
| Female | 63,023 (45.9) | 5659 (9.0) | 5399 (8.6) | 1439 (2.3) | 1379 (2.2) | 49,147 (78.0) |  |  |
| Male | 74,261 (54.1) | 7332 (9.9) | 6637 (8.9) | 1922 (2.6) | 1929 (2.6) | 56,441 (76.0) |  |  |
| Age group (years) |  |  |  |  |  |  | 475.07 | $<0.001$ |
| $[0,1]$ | 8417 (6.1) | 445 (5.3) | 775 (9.2) | 251 (3.0) | 265 (3.1) | 6681 (79.4) |  |  |
| $(1,2]$ | 13,806 (10.1) | 989 (7.2) | 1143 (8.3) | 330 (2.4) | 359 (2.6) | 10,985 (79.6) |  |  |
| $(2,5]$ | 38,485 (28.0) | 3486 (9.1) | 3582 (9.3) | 875 (2.3) | 957 (2.5) | 29,585 (76.9) |  |  |
| $(5,11]$ | 46,863 (34.1) | 4894 (10.4) | 4257 (9.1) | 1142 (2.4) | 1014 (2.2) | 35,556 (75.9) |  |  |
| $(11,18]$ | 29,713 (21.6) | 3177 (10.7) | 2279 (7.7) | 763 (2.6) | 713 (2.4) | 22,781 (76.7) |  |  |
| Quarter ${ }^{\text {a }}$ |  |  |  |  |  |  | 1312.36 | $<0.001$ |
| Q1 | 32,611 (23.8) | 3194 (9.8) | 3489 (10.7) | 1185 (3.6) | 1293 (4.0) | 23,450 (71.9) |  |  |
| Q2 | 22,901 (16.7) | 2249 (9.8) | 1833 (8.0) | 510 (2.2) | 489 (2.1) | 17,820 (77.8) |  |  |
| Q3 | 28,002 (20.4) | 3050 (10.9) | 2542 (9.1) | 614 (2.2) | 697 (2.5) | 21,099 (75.3) |  |  |
| Q4 | 53,770 (39.2) | 4498 (8.4) | 4172 (7.8) | 1052 (2.0) | 829 (1.5) | 43,219 (80.4) |  |  |

Table 2 (continued)

| Characteristic | Total, N (\%) | Appropriate use, n (\%) |  | Inappropriate use, n (\%) |  |  | Chi-square test |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Preferred medication | Antibiotic can be used or substituted | Combined use of antibiotics | Incorrect spectrum of antibiotics | Unnecessary use | $\mathrm{x}^{2}$ | $P$ value |
| Antibiotic route |  |  |  |  |  |  | 20,893.03 | $<0.001$ |
| Injection | 25,099 (18.3) | 1442 (5.7) | 3272 (13.0) | 2499 (10.0) | 2989 (11.9) | 14,897 (59.4) |  |  |
| Oral | 112,185 (81.7) | 11,549 (10.3) | 8764 (7.8) | 862 (0.8) | 319 (0.3) | 90,691 (80.8) |  |  |
| Insurance |  |  |  |  |  |  | 1006.17 | $<0.001$ |
| Fully out-ofpocket | 18,394 (13.4) | 1952(10.6) | 1982 (10.8) | 782 (4.3) | 860 (4.7) | 12,818 (69.7) |  |  |
| New rural cooperative medical system | 118,890 (86.6) | 11,039 (9.3) | 10,054 (8.5) | 2579 (2.2) | 2448 (2.1) | 92,770 (78.0) |  |  |
| ${ }^{\text {a }}$ Quarters |  |  |  |  |  |  |  |  |
| Q1: January-March |  |  |  |  |  |  |  |  |
| Q2: April-June |  |  |  |  |  |  |  |  |
| Q3: July-September |  |  |  |  |  |  |  |  |
| Q4: October - Decem | ber |  |  |  |  |  |  |  |

prescription of all antibiotics need not be used ( U : unnecessary use). For J03 (Acute tonsillitis), penicillin is preferred in more severe cases where bacterial infection is suspected (e.g., tonsillitis caused by streptococcus) ( P : preferred medication). Cephalosporins, macrolides, and quinolones also can be used. If lincosamides, aminoglycosides and nitroimidazoles were used, the antibiotic spectrum is incorrect (I: incorrect spectrum of antibiotics).
Lower respiratory tract infections, which include acute bronchitis (15.2\%) and bronchitis, not specified as acute or chronic (4.8\%), was the second most common childhood disease class in our study. Studies in China [36], Japan [31] and France [37] found that antibiotic prescription rates for bronchitis were $10.9 \%, 11.9 \%$ and $14.6 \%$, respectively. However, for bronchitis, it should be clear whether it is viral infection or bacterial infection. Viral infection without antibiotics. Suspected bacterial infection can be used penicillin intramuscular injection or oral cephalosporin [35]. Therefore, in Table 1, J20 (Acute bronchitis) shows that all antibiotics need not be used ( U : unnecessary use). For J40 (Bronchitis, not specified as acute or chronic), penicillins, cephalosporins, macrolides and quinolones shown antibiotic can be used or substituted (A: antibiotic can be used or substituted). If lincosamides, aminoglycoside, nitroimidazole were used, the antibiotic spectrum is incorrect (I: incorrect spectrum of antibiotics).
The use of antibiotics for acute upper respiratory tract infections of multiple and unspecified sites (J06) or acute bronchitis (J20) is inappropriate because it may trigger
allergies, infections, and even endanger the child's life [38]. This scenario likely to lead to ABR in children. The use of antibiotics in children is more likely to kill susceptible strains, leading to proliferation of resistant strains and replacement of susceptible strains, resulting in a sharp increase in drug resistance of bacteria [39].
In this study, the number of children diagnosed with acute otitis media and urinary tract infections was lower than other studies [37, 40]. Although otitis media usually occurs in children, otoscopy is necessary for a definitive diagnosis. Primary care institutions have the lowest testing capacity in China. They have no instrument to examine the inner ear canal. Most primary physicians also have no expertise in otorhinolaryngology. Patients with ear, nose and throat problems are referred to superior hospitals. In addition, in this study, we only analyzed systemic antibiotic prescriptions, excluding local antibiotic prescriptions such as ear drops. This may indirectly lead to low prescriptions for otitis media. For urinary tract infection, most primary care institutions are general outpatient departments, and primary physicians do not have professional knowledge of urinary system diagnosis and treatment. If a child develops symptoms of urinary tract infection, most patients will go to the specialized outpatient clinic of a superior hospital.

Overall, the unnecessary use of antibiotics occurred in all 10 systemic disease classifications in the study, accounting for $63.6 \%$ of all antibiotic prescriptions. This included diseases of the respiratory system (J06, J39, J00, J31, J20, J98, J21), diseases of the digestive system (K52, K30, K13, K08, K14, K59, K11, K92), diseases of the skin

Table 3 Factors predicting inappropriate use of antibiotics on multivariate analysis

| Characteristic | Adjusted OR (95\% CI) | $P$ value |
| :---: | :---: | :---: |
| Physician-related factors Sex: ref=Female |  |  |
| Male | 1.08 (1.04, 1.11) | <0.001 |
| Age: $\mathrm{ref}=23-32$ years |  |  |
| 33-40 | 1.17 (1.12, 1.22) | <0.001 |
| 41-65 | 1.38 (1.28, 1.49) | <0.001 |
| Professional title: ref = Associate chief physician |  |  |
| Attending physician | 1.83 (1.68, 2.00) | <0.001 |
| Resident physician | 1.42 (1.32, 1.54) | <0.001 |
| Education: ref = College |  |  |
| Junior college | 1.08 (1.05, 1.12) | <0.001 |
| Technical secondary school | 1.49 (1.42, 1.57) | <0.001 |
| Work duration: ref $=\leq 5$ (years) |  |  |
| 6-10 | 1.31 (1.26, 1.37) | <0.001 |
| 11-20 | 0.82 (0.77, 0.87) | <0.001 |
| 21-30 | 0.73 (0.67,0.80) | <0.001 |
| 31-39 | 0.53 (0.49, 0.58) | <0.001 |
| $\geq 40$ | 1.63 (1.40, 1.90) | <0.001 |
| Patient-related factors Sex: ref=Female |  |  |
| Male | 0.92 (0.90, 0.95) | <0.001 |
| Age: ref [0,1] (years) |  |  |
| (1,2] | 0.88 (0.81, 0.94) | <0.001 |
| $(2,5]$ | 0.70 (0.65, 0.75) | <0.001 |
| $(5,11]$ | $0.64(0.60,0.68)$ | <0.001 |
| $(11,18]$ | 0.69 (0.64, 0.74) | <0.001 |
| Quarter ${ }^{\text {a }}$ ref Q1 |  |  |
| Q2 | 1.00 (0.96, 1.05) | 0.8496 |
| Q3 | $1.10(1.06,1.15)$ | <0.001 |
| Q4 | 1.08 (1.05, 1.13) | <0.001 |
| Route: ref $=$ Injection |  |  |
| Oral | 0.96 (0.93, 1.00) | 0.0614 |
| Insurance: ref = Fully out-of-pocket |  |  |
| New rural cooperative medical system | 1.32 (1.27, 1.38) | <0.001 |

OR Odds ratio, CI Confidence interval, Ref Reference group
${ }^{\text {a }}$ Quarter
Q1: January-March
Q2: April-June
Q3: July-September
Q4: October-December
and subcutaneous tissue (L08, L23, L04, L30, L24, L50, L70), symptoms, signs and abnormal clinical and laboratory findings not elsewhere classified (R10, R05, R59, R50, R04, R07, R51, R22, R21, R11), injury, poisoning and certain other consequences of external causes (T14, T11), diseases of the genitourinary system (N39, N48), diseases of the circulatory system (I88, I84, I67), diseases of the ear and mastoid process (H65, H61), certain infectious and parasitic diseases (B00, A08, B08), and diseases of the eye and adnexa (H02). It should be noted that the 10
sub-diseases under symptoms, signs and abnormal clinical and laboratory findings not elsewhere classified (R10, R05, R59, R50, R04, R07, R51, R22, R21, R11) were all diseases for which antibiotics are unnecessary. The rate of inappropriate antibiotics use for these diseases often reached $100 \%$. When treating such childhood diseases, physicians should make specific clinical diagnoses based on typical signs and symptoms [17,28]. It is particularly important to stress that when physicians suspect a child has severe pneumonia according to typical signs and
symptoms, the child should be transferred to a superior hospital in a timely manner [41]. According to National Health Commission of China for Guiding Principle of Clinical Use of Antibiotics introduced in 2015, there is a very limited range of antibiotics suitable for use by those aged 18 years and under [17]. Physicians should be more cautious about prescribing antibiotics for children as widespread use could exacerbate ABR.

We also found from those antibiotic prescriptions with incorrect spectrum of antibiotics accounted for $2.4 \%$ of all antibiotic prescriptions. Except for the systemic disease of symptoms, signs and abnormal clinical and laboratory findings not elsewhere classified, the other 9 systemic diseases all had the condition of incorrect spectrum of antibiotics. Diseases of the eye and adnexa had the highest proportion of incorrect spectrum of antibiotics ( $37.0 \%$ ). The proportion of incorrect spectrum of antibiotics was highest in the sub-disease (keratitis) of diseases of the eye and adnexa (97.8\%). Penicillins, cephalosporins, macrolides, lincosamides and nitroimidazoles are the incorrect spectrum of antibiotics for these particular diseases. According to Ophthalmology Clinical Guidelines of American Academy of Ophthalmology (2nd edition) [42], Ophthalmology of China (9th edition) [43] and National Health Commission of China for Guiding Principle of Clinical Use of Antibiotics introduced in 2015 [17], quinolones and aminoglycosides are the preferred medication treatment of keratitis treatment, especially in children.
In our study, "Incorrect spectrum of antibiotics" (2.4\%) and "Combined use of antibiotics" ( $2.4 \%$ ) were the two types of inappropriate antibiotics use that accounted for the least proportion. The proportion of "Incorrect spectrum of antibiotics" in this study was low, mainly because the proportion was distributed differently among different diseases. For example, the proportion for keratitis and acute myocarditis was more than $75 \%$ of cases. The low inappropriate rate of "Combined use of antibiotics" was primarily due to the absence of diseases such as tuberculosis, leprosy or other diseases requiring combination therapy in primary care institutions [29]. In addition, we used a very strict definition of drug combinations: more than one systemic antibiotic by injection or oral administration at a time by an outpatient physician without any indication. Previous studies [44-46] have raised the issue of antibiotic combinations. Therefore, even if the numbers are low, "Incorrect spectrum of antibiotics" and "Combined use of antibiotics" are still a non-negligible problem in antibiotic prescription overuse.
In our study, the majority of inappropriate antibiotic prescriptions were prescribed by physicians older than 40 years, with lower professional titles (resident physician / attending physician) and more than 40 years of work
duration. Their education was mostly non-undergraduate, and their professional knowledge and experience are often inadequate. Based on this result, it may be necessary to provide refresher courses in antibiotic prescribing for these primary care physicians [47, 48]. Training should emphasize avoiding incorrect and unnecessary use of antibiotic prescriptions in children.
In this study, children insured by new rural cooperative medical system were more likely to be prescribed inappropriate antibiotics than those who had to pay fully out-of-pocket. One possible reason is that many antibiotics in China are included in the National Essential Medicine List [49]. The children enrolled in the new rural cooperative medical system can use these antibiotics for free or partially free. This increases the risk of inappropriate use of antibiotics. Therefore, it is necessary to educate the physicians and patients about the dangers of inappropriate use of antibiotics, so as to establish a correct concept of medication.
The proportion of antibiotics prescribed inappropriately was higher in the third and fourth quarters compared to the first quarter of the year. This may be due to the higher incidence of infectious diseases in autumn and winter [50]. However, most of treated patients were diagnosed with viral infectious diseases.
We also found that inappropriate antibiotic prescriptions in children may be correlated with sex of children. This may be related with the fact that left-behind children in rural areas of China are often cared for by poorly educated grandparents, as well as sex discrimination. In addition, children aged $0-1$ were more likely than any other age group to be prescribed inappropriate antibiotics. In our team's preliminary survey of primary care institutions in Guizhou Province, we found that the educational level of child caregivers was low and were unaware of the dangers of antibiotic resistance. They generally believe that antibiotics are a panacea. However, infants have an immature immune function, weak anti-infection ability, and are prone to various diseases [51]. In order to heal infants as quickly as possible, the caregivers often ask the physicians for prescriptions of antibiotics [52]. This may increase the risk of inappropriate antibiotic use in the infants. Therefore, more information about antibiotic use, such as easy-to-understand brochures and learning videos, should be provided to caregivers of children.
In China, during the COVID-19 pandemic in 2020, the National Health Commission noted that primary care institutions had the lowest level of access and treatment conditions than secondary and above hospitals. Therefore, they were not eligible for COVID-19 treatment. All suspected febrile patients are transferred to a secondary or higher-level hospital for treatment. Therefore, there were no febrile patients in outpatient clinics of primary
care institutions. No COVID-19 related patients were seen in this study.
Our study has several limitations. First, the study subjects in primary care institutions may not fully represent the general population of children in China. Second, the time frame of the survey was limited to 1 year, thus we could not judge whether the prevalence of pediatric diseases and antibiotic use differed over several years [53, 54]. Third, the primary care institutions in Guizhou Province generally do not do laboratory testing; the physicians give drugs by experience. Therefore, we cannot find relevant content for further analysis in HIS system. Fourth, due to being unable to obtain more etiological information, the clinical pharmacists in our team can only assume that "the cause of acute pharyngitis and acute tonsillitis is Group A Hemolytic Streptococcus infection (GABHS)". Hence, the unnecessary use antibiotics may be underestimated.

## Conclusions

The inappropriate use of antibiotics in children is still prominent in primary care institutions in Guizhou, China. Unnecessary use of antibiotics for many diseases and the inappropriate use of lincosamides and aminoglycosides in children in primary care were the main clinical problems of rural children. The education and training of physicians and caregivers in primary care institutions should be strengthened.

## Abbreviations

ABR: Antibiotic resistance; ICD-10: the 10th Edition of the International Classification of Diseases; CDC: Centers for Disease Control and Prevention; HIS: Hospital Information System; LWTC: LianKe Weixin Co., LTD.; OR: Odds ratio; Cl: Confidence interval; Ref: Reference group.

## Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12875-022-01875-9.

Additional file 1. Catalogue for Clinical Application of Antibacterial Drugs.
Additional file 2. National Health Commission of China for Guiding Principle of Clinical Use of Antibiotics.

## Acknowledgments

We thank all the participating institutions for providing information and assistance during the study. The authors also thank all members of the investigational team who collected the data. We acknowledge the assistance of Edward McNeil, Prince of Songkla University, Songkhla, Thailand for reading the manuscripts and making suggestions to improve it.

## Authors' contributions

All authors made substantial contributions to the research, and read and approved the final manuscript. YC, XRZ, LW designed the research. WWJ drafted the manuscript, and WWJ and YC completed data extraction, statistical analysis and data interpretation. YC, STY, XH, and HNZ participated in the concept, data interpretation and manuscript revision. WWJ and $Y C$ is
responsible for data integrity and accuracy of data analysis. The author(s) read and approved the final manuscript.

## Funding

This research was funded by National Natural Science Foundation of China Grant on "Research on feedback intervention mode of antibiotic prescription control in primary medical institutions based on the depth graph neural network technology" (71964009) and Technology Fund Project of Guizhou Provincial Health Commission Grant on "Application Research of Deep Learning Technology in Rational Evaluation and Intervention of Antibiotic Prescription" (gzwjkj2019-1-218). The funders provided travel expenses during the data collection process, as well as the expert's expenses for providing guidance on the study design, technological guidance, data analysis, interpretation of data and guidance on the manuscript writing.

## Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Declarations

## Ethics approval and consent to participate

The study was approved by the Review Committee of Guizhou Medical University (Approval Certificate No. 2019(149)). In our manuscript, the participants were physicians. We only focused on children's prescriptions. As a result, we only saw these physicians prescribing children without reaching these children. In addition, after signing the confidentiality agreement, Guizhou Provincial Health Commission agreed that we would only sign the informed consent form with the physicians. So, all participants (physicians) provided written informed consent to participate in the study. A tripartite agreement was signed between Guizhou Provincial Health Commission, Guizhou Medical University and LWTC Company. The prescription information was authorized by the Information Center of Guizhou Provincial Health Commission, and downloaded from the data port of HIS system developed by LWTC. After downloading the prescription, all identifying information about the physicians and patients is hidden, as required by confidentiality agreements. So, the data used in this study was anonymized before its use. Furthermore, we only downloaded the prescription and did not have access to the children or obtain written informed consent from the children's guardians.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

${ }^{1}$ School of Public Health, Guizhou Medical University, Guiyang, Guizhou Province, China. ${ }^{2}$ Guiyang Public Health Clinical Center, Guiyang, Guizhou Province, China. ${ }^{3}$ Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China. ${ }^{4}$ Primary Health Department of Guizhou Provincial Health Commission, Guiyang, Guizhou Province, China. ${ }^{5}$ School of Medicine and Health Management, Guizhou Medical University, Guiyang, Guizhou Province, China.

Received: 4 April 2022 Accepted: 5 October 2022
Published online: 26 October 2022

## References

1. World Health Organization. Global action plan on antimicrobial resistance. Available online: https://www.who.int/publications/i/item/97892 41509763. (Accessed on 01 Dec 2021).
2. Xue F, Xu B, Shen A, Shen K. Antibiotic prescriptions for children younger than 5 years with acute upper respiratory infections in China: a retrospective nationwide claims database study. BMC Infect Dis. 2021;21(1):339.
3. National Health Commission of People's Republic of China. Regulation Standard for Hospital Prescription Review. Available online: http://www.
nhc.gov.cn/wjw/ywfw/201306/094ebc83dddc47b5a4a63ebde7224615. shtml. (Accessed on 01 Dec 2021).
4. French National Authority for Health. Antibiotic therapy and prevention of bacterial resistance in healthcare organisations. Available online: https://www.hassante.fr/upload/docs/application/pdf/201003/antib iotic_therapy_and_prevention_of_bacterial_resistance-guidelines. (Accessed on 01 Dec 2021).
5. Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System. 2017 report. Ottawa: Public Health Agency of Canada; 2017.
6. Australian Commission on Safety and Quality in Health Care. Antimicrobial Stewardship in Australian Health Care 2018. Sydney: ACSQHC; 2018.
7. Antibiotic awareness: important messages on antibiotic use. Available online: https://www.gov.uk/government/publications/european-antib iotic-awareness-day-key-messages-on-antibiotic-use (Accessed on 01 Dec 2021).
8. The White House. National action plan for combating antibiotic resistant bacteria, [EB/OL]. Available online: https://www.whitehouse.antibotic-resistant-bacteria.pdf. (Accessed on 01 Dec 2021).
9. Mclsaac W, Kukan S, Huszti E, Szadkowski L, O’Neill B, Virani S, et al. A pragmatic randomized trial of a primary care antimicrobial stewardship intervention in Ontario, Canada. BMC Fam Pract. 2021;22(1):185.
10. Blair PS, Turnbull S, Ingram J, Redmond N, Lucas PJ, Cabral C, et al. Feasibility cluster randomised controlled trial of a within-consultation intervention to reduce antibiotic prescribing for children presenting to primary care with acute respiratory tract infection and cough. BMJ Open. 2017;7(5):e014506.
11. Shen X, Lu M, Feng R, Cheng J, Chai J, Xie M, et al. Web-based just-intime information and feedback on antibiotic use for village doctors in rural Anhui, China: randomized controlled trial. J Med Internet Res. 2018;20(2):e53.
12. Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. JAMA. 2016;315(6):562-70.
13. Magin P, Tapley A, Morgan S, Davis JS, McElduff P, Yardley L, et al. Reducing early career general practitioners' antibiotic prescribing for respiratory tract infections: a pragmatic prospective non-randomised controlled trial. Fam Pract. 2018;35(1):53-60.
14. Ferrat E, Le Breton J, Guéry E, Adeline F, Audureau E, Montagne O, et al. Effects 4.5 years after an interactive GP educational seminar on antibiotic therapy for respiratory tract infections: a randomized controlled trial. Fam Pract. 2016;33(2):192-9.
15. Hsia Y, Sharland M, ackson C, Wong ICK, Magrini N, Bielicki JA. Consumption of oral antibiotic formulations for young children according to the WHO access, watch, reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19(1):67-75.
16. National Health Commission of the People's Republic of China. Status report on antimicrobial administration in the People's Republic of China, 2021. Beijing: China Union Medical College Press; 2021. p. 25.
17. National Health Commission of the People's Republic of China. Guiding Principle of Clinical Use of Antibiotics introduced in 2015. Available online: http://www.nhc.gov.cn/ewebeditor/uploadfile/2015/09/20150 928170007470. pdf. (Accessed on 01 Dec 2021).
18. Wushouer H, Du K, Chen S, Zhou Y, Zheng B, Guan X, et al. Outpatient antibiotic prescribing patterns and appropriateness for children in primary healthcare settings in Beijing City, China, 2017-2019. Antibiotics (Basel, Switzerland). 2021;10(10):1248.
19. Marc C, Vrignaud B, Levieux K, Robine A, Guen CG, Launay E. Inappropriate prescription of antibiotics in pediatric practice: analysis of the prescriptions in primary care. J Child Health Care. 2016;20(4):530-6.
20. Iftikhar S, Sarwar MR, Saqib A, Sarfraz M, Shoaib QU. Antibiotic prescribing practices and errors among hospitalized pediatric patients suffering from acute respiratory tract infections: a multicenter, cross-sectional study in Pakistan. Medicina (Kaunas). 2019;55(2):44.
21. McMullan BJ, Hall L, James R, Mostaghim M, Jones CA, Konecny P, et al. Antibiotic appropriateness and guideline adherence in hospitalized children: results of a nationwide study. J Antimicrob Chemother. 2020;75(3):738-46.
22. Bianco A, Licata F, Nobile CG, Napolitano F, Pavia M. Pattern and appropriateness of antibiotic prescriptions for upper respiratory tract infections in primary care paediatric patients. Int J Antimicrob Agents. 2022;59(1):106469.
23. Wang ZX, Lei L, Huang FH, Na L. Analysis of rationality of prescription drug use in 45 basic hospitals in a district. China Pharm. 2018;27(17):86-9.
24. Hang LLL, Wang Y, Xue D, Liu SX, Fang PQ. Hospital administration. 2th ed. Beijing: People's Medical Publishing House; 2014. p. 5.
25. United Nations. Convention on the Rights of the Child. 1989. Available online: https://www.un.org/zh/documents/treaty/files/A-RES-44-25. shtml. (Accessed on 01 Dec 2021).
26. Central People's Government of the People's Republic of China. Law of the People's Republic of China on the Protection of Minors. Available online: http://www.gov.cn/banshi/2005-05/26/content_982.htm. (Accessed on 20 June 2022).
27. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available online: https://icd.who.int/browse10/2016/en (Accessed on 01 Dec 2021).
28. Centers for Disease Control and Prevention. Antibiotic Prescribing and Use in Doctor's Offices. 2017. Available online: https://www.cdc.gov/ antibiotic-use/community/for-hcp/outpatient-hcp/adult-treatment-rec. html (Accessed on 01 Dec 2021).
29. Chang Y, Chusri S, Sangthong R, McNeil E, Hu J, Du W, et al. Clinical pattern of antibiotic overuse and misuse in primary healthcare hospitals in the southwest of China. PLoS One. 2019;14(6):e0214779.
30. Mihani J, Këlliçi S. Patterns of antibiotic prescription in children: Tirana, Albania region. Open Access Maced J Med Sci. 2018;6(4):719-22.
31. Yoshida S, Takeuchi M, Kawakami K. Prescription of antibiotics to pre-school children from 2005 to 2014 in Japan: a retrospective claims database study. J Public Health (Oxf). 2018;40(2):397-403.
32. Karinauske E, Kasciuskeviciute S, Morkuniene V, Garuoliene K, Kadusevicius E. Antibiotic prescribing trends in a pediatric population in Lithuania in 2003-2012: observational study. Medicine. 2019;98(46):e17220.
33. Messina F, Clavenna A, Cartabia M, Piovani D, Bortolotti A, Fortino I, et al. Antibiotic prescription in the outpatient paediatric population attending emergency departments in Lombardy, Italy: a retrospective database review. BMJ Paediatr Open. 2019;3(1):e000546.
34. Wang CN, Huttner BD, Magrini N, Cheng Y, Tong J, Li S, et al. Pediatric antibiotic prescribing in China according to the 2019 World Health Organization access, watch, and reserve (AWaRe) antibiotic categories. J Pediatr. 2020;220:125-31.
35. Zhou JY, Song MY, Sun SF, Xie GL. Practical diagnosis and treatment of pediatric diseases. Beijing: Science Press; 2021. p. 38-9.
36. Lee ML, Cho CY, Hsu CL, Chen CJ, Chang LY, Lee YS, et al. Recent trends in antibiotic prescriptions for acute respiratory tract infections in pediatric ambulatory care in Taiwan, 2000-2009: a nationwide population-based study. J Microbiol Immunol Infect. 2016;49(4):554-60.
37. Touboul-Lundgren P, Bruno P, Bailly L, Dunais B, Pradier C. Paediatric antibiotic prescriptions in primary care in the Alpes-Maritimes area of southeastern France between 2008 and 2013. Eur J Clin Microbiol Infect Dis. 2017;36(3):509-16.
38. Huang YW. Abuse of antibiotics in children is harmful. Fam Med. 2021;06:13.
39. Chen H. Harm of misuse of antibiotics in children. Modern Drug Appl China. 2014;8(17):213-4.
40. Mathew R, Sayyed H, Behera S, Maleki K, Pawar S. Evaluation of antibiotic prescribing pattern in pediatrics in a tertiary care hospital. Avicenna J Med. 2021;11(1):15-9.
41. Wang Q, Chang Y, Cui ZZ, Yu ST, Wang L, Fan XY. Formulation of recommendation manual for diagnosis and evaluation of rational use of antibacterial agents for bacterial infectious diseases in primary hospitals (respiratory part). Herald Med. 2022;41(5):112-21.
42. American Academy of ophthalmology. Clinical guidelines for ophthalmology. In: Chinese Society of Ophthalmology, Chinese Medical Association, translated. 2nd ed. Beijing: People's Medical Publishing House; 2013. p. 217-314.
43. Zhao K, Yang PZ, Fan XQ, Sun XH, Liu YZ, Zhao GQ, et al. Ophthalmology. 9th ed. Beijing: People's Medical Publishing House; 2018. p. 107-17.
44. Adisa R, Orherhe OM, Fakeye TO. Evaluation of antibiotic prescriptions and use in under-five children in Ibadan, SouthWestern Nigeria. Afr Health Sci. 2018;18(4):1189-201.
45. Yehualaw A, Taferre C, Bantie AT, Demsie DG. Appropriateness and pattern of antibiotic prescription in pediatric patients at Adigart general hospital, Tigray, Ethiopia. Biomed Res Int. 2021;2021:6640892.
46. Gizework A, Seyfe AA. Assessment of the pattern of antibiotics use in pediatrics ward of Dessie referral hospital, north East Ethiopia. Int J Med Med Sci. 2015;7(1):1-7.
47. Xiao YH, Wang J, Shen P. Retrospective survey of the efficacy of mandatory implementation of the essential medicine policy in the primary healthcare setting in China: failure to promote the rational use of antibiotics in clinics. Int J Antimicrob Agents. 2016;48(4):409-14.
48. Wang J, Wang P, Wang X. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med. 2014;174(12):1914-20.
49. National health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine. Notice on the issuance of the National Essential Medicine Catalogue (2018 ed). Available online: http://www.nhc.gov.cn/yaozs/s7656/201810/c18533e22a3940d08d99 6b588d941631.shtml (Accessed on 25 June 2022).
50. Vandini S, Corvaglia L, Alessandroni R, Aquilano G, Marsico C, Spinelli M, et al. Respiratory syncytial virus infection in infants and correlation with meteorological factors and air pollutants. Ital J Pediatr. 2013;39(1):1.
51. Wang WP, Sun K, Chang LW, Shen KL, Li Q, Du LZ, et al. Pediatrics. 9th ed. Beijing: People's Medical Publishing House; 2018. p. 3.
52. Li WR. Study of countermeasures of rational antibiotic use in children. Med Jurisprudence. 2022;14(02):48-52.
53. Fortanier AC, Venekamp RP, Stellato RK, Sanders EAM, Damoiseaux RAMJ, Hoes AW, et al. Outpatient antibiotic use in Dutch infants after 10-valent pneumococcal vaccine introduction: a time-series analysis. BMJ Open. 2018;8(6):e020619.
54. Rolf von den BT, Crosby M, Tadrous M, Schwartz KL, Gomes T. Measuring the impacts of the using antibiotics wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. J Antimicrob Chemother. 2021;76(9):2472-8.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100 M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
BMC


[^0]:    ${ }^{\dagger}$ Wenju Wang, Shitao Yu and Yue Chang contributed equally to this work.
    *Correspondence: 4567401@qq.com; 2398662779@qq.com; 595388939@qq.com
    ${ }^{5}$ School of Medicine and Health Management, Guizhou Medical University, Guiyang, Guizhou Province, China
    ${ }^{3}$ Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou Province, China
    ${ }^{4}$ Primary Health Department of Guizhou Provincial Health Commission, Guiyang, Guizhou Province, China
    Full list of author information is available at the end of the article

